Trials / Recruiting
RecruitingNCT07209111
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Calderasib | Oral administration |
| BIOLOGICAL | Cetuximab | Intravenous administration |
Timeline
- Start date
- 2025-12-04
- Primary completion
- 2032-04-09
- Completion
- 2032-04-09
- First posted
- 2025-10-06
- Last updated
- 2026-04-13
Locations
44 sites across 15 countries: United States, Australia, China, Denmark, Germany, Greece, Israel, Italy, Norway, Poland, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07209111. Inclusion in this directory is not an endorsement.